Updated:
Tute Genomics
Tute Genomics provides a cloud platform for genomic data interpretation, used by researchers and clinicians to identify disease genes and biomarkers.
Tute Genomics
Tute Genomics was founded to address the bottleneck in genomic data analysis—interpreting the millions of variants in a human genome. The company markets its cloud platform to academic medical centers, diagnostic labs, and pharmaceutical research groups, positioning itself as an infrastructure layer for precision medicine. The firm's strategy centers on software-as-a-service deployment, with a client base concentrated in North America. It covers whole-exome, whole-genome, and panel sequencing data, and integrates with existing laboratory information systems. Named clients or deployments are not publicly listed in available sources. The platform applies machine learning to rank variants by pathogenicity, supporting both research and clinical reporting workflows. Tute Genomics has not disclosed its team size, funding history, or total deployment. Its website lists offices in Newark, Chicago, and Salt Lake City, but does not name executives, investors, or a founding year. No recent operational events or partnerships are publicly available. The structural differentiator for Tute Genomics is its pure-play bioinformatics focus—it has not expanded into lab testing, device manufacturing, or drug development. That narrow vertical scope makes it a tool provider rather than a diagnostics company, which shapes its revenue model and competitive positioning.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Newark
Corporate office
Newark, Chicago, Salt Lake City, United States
Sector focus
Frequently asked questions
What does Tute Genomics' platform actually do?
Tute Genomics' cloud-based platform automates the annotation, filtering, and prioritization of genetic variants from DNA sequencing data. It helps users find disease-causing mutations and biomarkers by ranking variants according to pathogenicity, population frequency, and functional impact.
Who is the typical customer for Tute Genomics?
Typical customers include academic and medical research institutions, clinical diagnostic laboratories, and pharmaceutical R&D teams. The platform is designed for laboratories that process whole-exome, whole-genome, or targeted panel sequencing and need a scalable interpretation pipeline.
Does Tute Genomics develop its own sequencing technology or tests?
No. Tute Genomics is a software-only company; it does not manufacture sequencing machines or offer direct-to-consumer genetic tests. Its role is to analyze data generated by other sequencing platforms.
Is Tute Genomics a family office or investment vehicle?
The available public information describes Tute Genomics as an operating company, not a family office or asset manager. It sells a software product.
What investment or funding history does Tute Genomics have?
Tute Genomics has not publicly disclosed any funding rounds, investors, or ownership structure. No venture capital or private equity involvement is visible in public sources.
Who founded or leads Tute Genomics?
The company's website and public records do not name any founders, executives, or board members. This information is not disclosed.
In which geographies does Tute Genomics operate?
The company lists offices in Newark (New Jersey), Chicago (Illinois), and Salt Lake City (Utah), all within the United States. It may serve international clients, but no specific international presence is stated.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: